Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Shares Outstanding (2016 - 2025)

Cytokinetics (CYTK) has disclosed Shares Outstanding for 16 consecutive years, with $122.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding changed N/A to $122.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $122.9 million through Dec 2025, changed N/A year-over-year, with the annual reading at $122.9 million for FY2025, N/A changed from the prior year.
  • Shares Outstanding for Q4 2025 was $122.9 million at Cytokinetics, up from $122.1 million in the prior quarter.
  • The five-year high for Shares Outstanding was $122.9 million in Q4 2025, with the low at $71.6 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $99.3 million, with a median of $95.9 million recorded in 2023.
  • The sharpest move saw Shares Outstanding grew 22.5% in 2024, then rose 1.77% in 2025.
  • Over 5 years, Shares Outstanding stood at $83.8 million in 2021, then rose by 13.13% to $94.8 million in 2022, then grew by 7.17% to $101.6 million in 2023, then rose by 15.99% to $117.9 million in 2024, then rose by 4.29% to $122.9 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $122.9 million, $122.1 million, and $119.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.